AstraZeneca PLC

AZNNYSEHealthcare● Active

$184.12

$-1.84(-0.99%)

Market Cap$285.5B

P/E Ratio—

52W High$212.71

52W Low$137.22

Avg Volume1.9M

Open$184.16

Beta0.21

Overview

AstraZeneca PLC (AZN) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

azn · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for AstraZeneca PLC (AZN) measures how much investors pay for each dollar of the company's trailing earnings. AZN's current PE ratio of 27.33x is calculated by dividing its stock price of $184.12 by its TTM earnings per share of $6.75. −91.6% discount vs 5Y avg 324.2x

27.33x

P/E Ratio (TTM)−91.6%

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E

15.80x

FY2027 est. EPS $11.65

Based on 7 analysts

EPS (TTM)

$6.75

TTM · diluted EPS

PEG Ratio

0.83

Below 1.0 · Growth adjusted

▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · AstraZeneca PLC SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2006 – 2025 · Annual

PE Ratio (TTM)

5Y Avg 324.2x

EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

Historical PE Range

Past 20 fiscal years · Front-end computed

Average

102.7x

20-yr mean

Median

28.7x

20-yr midpoint

Minimum

6.4x

Lowest year

Maximum

1466.7x

Highest year

27.3x ← Now

6.4x
MinQ1 · 25%28.7x
MedianQ3 · 75%1466.7x
Max

Within Historical Range

At 27.33x, AZN's current P/E is within its average historical range over the past 20 fiscal years.

45th percentileHigher than 9 of 20 historical fiscal year readings

Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.

PE Ratio vs Peers

Drug Manufacturers - General · 6 peers · Annual PE

Company	Market Cap	PE (Annual)	vs Avg	EPS (TTM)
AstraZeneca PLCYou AZN	$285.5B	27.33x	-7.8%	$6.75
AbbVie Inc. ABBV	$393.7B	96.26x	+224.7%	$2.37
Amgen Inc. AMGN	$186.9B	22.84x	-23.0%	$14.33
Bristol-Myers Squibb Company BMY	$115.4B	15.61x	-47.4%	$3.46
Gilead Sciences, Inc. GILD	$159.5B	17.94x	-39.5%	$6.84
GSK plc GSK	$102.4B	6.45x	-78.3%	$5.64
Johnson & Johnson JNJ	$558.9B	18.81x	-36.6%	$11.04
Industry Average 6 peers with valid PE	—	29.65x	baseline	—

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 10 of 20 years

Fiscal Year End	PE Ratio	EPS (TTM)	YoY Change
2025-12-31Latest FY2025	26.53x	$6.62	-7.4%
2024-12-31 FY2024	28.64x	$4.54	-17.8%
2023-12-31 FY2023	34.84x	$3.81	-45.7%
2022-12-31 FY2022	64.13x	$2.12	-95.6%
2021-12-31 FY2021	1466.74x	$0.08	+3437.6%
2020-12-31 FY2020	41.46x	$2.44	-57.9%
2019-12-31 FY2019	98.43x	$1.03	+120.4%
2018-12-31 FY2018	44.66x	$1.70	+54.3%
2017-12-31 FY2017	28.94x	$2.37	+48.6%
2016-12-31 FY2016	19.48x	$2.77	-35.7%

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

PE Ratio = Stock Price ÷ EPS (TTM)

= $184.12 ÷ $6.75 = 27.33x

TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures

Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year

PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium

Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Price history Financial statements Earnings

Frequently asked questions

AZN pe ratio · 6 questions

AZN's current PE ratio is 27.33x as of 2026-06-08, based on a stock price of $184.12 and TTM EPS of $6.75. Data sourced from Financial Modeling Prep via AZN's SEC 10-K and 10-Q filings.

AZN PE ratioWhat is AZN PE ratioCurrent PE ratio of AZNAZN PE ratio today

▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · AstraZeneca PLC SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08